Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy

Abstract

Chimeric antigen receptors containing TSLPR-CD19 and TSLPR-CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

What is claimed is: 
     
       1. A method of treating a B-cell hematological cancer in a human subject in need thereof, the method comprising administering to the human subject a pharmaceutical composition comprising an effective amount of a population of autologous T cells, wherein the autologous T cells comprise a nucleic acid sequence that encodes a CD19-TSLPR tandem chimeric antigen receptor (CAR) or a CD22-TSLPR tandem CAR, wherein the CD19-TSLPR tandem CAR or the CD22-TSLPR tandem CAR comprises the amino acid sequence comprising SEQ ID NO: 87, 91, or 95, thereby treating the B-cell hematological cancer of the human subject. 
     
     
       2. The method of  claim 1 , wherein the CD19-TSLPR tandem CAR or the CD22-TSLPR tandem CAR is encoded by a nucleotide sequence comprising SEQ ID NO. 86, 90, or 94, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof. 
     
     
       3. The method of  claim 1 , wherein the B-cell hematological cancer is leukemia, lymphoma or multiple myeloma. 
     
     
       4. The method of  claim 3 , wherein the leukemia is chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), or chronic myelogenous leukemia (CML). 
     
     
       5. The method of  claim 3 , wherein the lymphoma is mantle cell lymphoma, non-Hodgkin's lymphoma or Hodgkin's lymphoma.